tldrdaily.news logo
Tag

Growth Hormone Deficiency

All articles tagged with #growth hormone deficiency

business2 years ago

"Pfizer's Hidden Potential: Uncovering the Undervalued Gem on NYSE"

Pfizer's financial position is expected to benefit from recent events, including multiple drug and vaccine approvals, which will help offset potential revenue losses from exclusivity and reduced demand for the COVID-19 vaccine. The company's experimental drug, danuglipron, is poised to compete with leaders in the diabetes treatment market. Additionally, the FDA approval of Abrysvo for respiratory syncytial virus in older people opens up significant commercial opportunities. The recent FDA approvals of Litfulo and Ngenla further strengthen Pfizer's position in the pharmaceutical industry. Ngenla's entry into the US market is expected to drive strong sales growth and profit generation. With extensive long-term data and market recognition, Pfizer aims to regain its share of the global human growth hormone market. Despite a recent decrease in share price, technical analysis suggests a potential reversal upwards. The article concludes with an "outperform" rating for Pfizer.

via Seeking Alpha|
#business#drug-approvals#growth-hormone-deficiency
healthcare2 years ago

FDA Approves Pfizer-OPKO's NGENLA™ for Pediatric Growth Hormone Deficiency and Severe Alopecia

The U.S. Food and Drug Administration has granted approval to Pfizer and OPKO Health's treatment for growth hormone deficiency in children. The injectable hormone therapy, known as Ngenla, will be sold under the brand name Ngenla and is intended for pediatric patients aged three years and older. The once-weekly injection will be priced at around $8,300 per month. Pfizer plans to offer benefits to reduce out-of-pocket costs and improve access to the drug, which is expected to be available in the U.S. in August. Ngenla will compete with Ascendis Pharma's once-weekly growth hormone injection, Skytrofa, which was approved by the FDA in 2021.

via AOL|
#fda-approval#growth-hormone-deficiency#healthcare
healthcare2 years ago

FDA Approves Pfizer-OPKO's NGENLA™ for Pediatric Growth Hormone Deficiency and Alopecia Areata

Pfizer and OPKO Health have received approval from the U.S. Food and Drug Administration for their treatment for growth hormone deficiency in children. The once-weekly injectable hormone therapy, sold under the brand name Ngenla, will be available in the U.S. in August. The approval lifted Pfizer's shares marginally and Opko Health's nearly 19% in premarket trading. Ngenla will compete with Ascendis Pharma's once-weekly growth hormone injection, Skytrofa, which was approved by the FDA in 2021.

via Yahoo Finance|
#fda-approval#growth-hormone-deficiency#healthcare